🟢 Veru is trading 10.37% up today as Oppenheimer reaffirmed Outperform and $24 target

Veru is trading at $2.35, up +10.37%, after Oppenheimer reaffirmed its Outperform rating and $24 price target.

• The reaffirmation is a company-specific bullish signal ahead of anticipated enobosarm trial data.
• An interim analysis of the Phase 2b PLATEAU study, evaluating enobosarm with semaglutide, is expected next quarter; the trial is fully enrolled with 239 patients.
• The sharp intraday gain follows recent declines; broader conditions are mixed, while biotech is higher. Live-session volume details were unavailable.